喀什割包皮手术大概价格(喀什包皮手术几天恢复) (今日更新中)

LOS ANGELES, July 6 (Xinhua) -- NASA scientists have got the first-ever, up-close details of a Saturn storm that is eight times the surface area of Earth, the Jet Propulsion Laboratory ( JPL) announced on Wednesday.The images were captured by NASA's Cassini spacecraf, according to JPL in Pasadena, Los Angeles.On Dec. 5, 2010, Cassini first detected the storm that has been raging ever since. It appears approximately 35 degrees north latitude of Saturn.The storm is the biggest observed by spacecraft orbiting or flying by Saturn. NASA's Hubble Space Telescope captured images in 1990 of an equally large storm.Pictures from Cassini's imaging cameras show the storm wrapping around the entire planet covering approximately two billion square miles (4 billion square kilometers).The storm is about 500 times larger than the biggest storm previously seen by Cassini during several months from 2009 to 2010. At its most intense, the storm generated more than 10 lightning flashes per second.Cassini has detected 10 lightning storms on Saturn since the spacecraft entered the planet's orbit.Those storms rolled through an area in the southern hemisphere dubbed "Storm Alley." "Cassini shows us that Saturn is bipolar," said Andrew Ingersoll, a Cassini imaging team member at the California Institute of Technology in Pasadena, California. "Saturn is not like Earth and Jupiter, where storms are fairly frequent. Weather on Saturn appears to hum along placidly for years and then erupt violently. I'm excited we saw weather so spectacular on our watch."The new details about this storm complement atmospheric disturbances described recently by scientists using Cassini's composite infrared spectrometer and the European Southern Observatory's Very Large Telescope. The Cassini-Huygens mission is a cooperative project of NASA, the European Space Agency and the Italian Space Agency. NASA's JPL manages the mission for the agency's Science Mission Directorate in Washington.

WARSAW, June 7 (Xinhua) -- Another patient suspected of Escherichia coli was admitted to hospital in Gizycko, northeastern Poland, on Tuesday, local media reported.On Monday Poland's first E. coli infection case was confirmed by tests conducted by the National Institute of Hygiene.Poland's first E. coli patient, a 29-year-old woman permanently residing in Germany and diagnosed with the bacteria, has been receiving treatment in a hospital in Szczecin in northwestern Poland for over two weeks.Two men suspected of E. coli have been hospitalized in Szczecin. They both had returned from Germany shortly before they fell ill. Another man suspected of E. coli was hospitalized in Ostroleka in central Poland also returned from Germany.A boy with haemolytic-uraemic syndrome (HUS), a disease characterized by hemolytic anemia caused by the E.coli patogenic bacteria, has been hospitalized in a Warsaw hospital.The E. coli epidemic originated in Germany. The Robert Koch Institute said the number of registered infections in Germany rose to 2,325 Tuesday, with those in other European countries still standing at about 100. The outbreak has killed a total of 23 people across Europe in the past month.

BEIJING, Sept. 14 (Xinhuanet) -- The U.S. Food and Drug Administration (FDA) on Monday announced a recall on a drug infusion pump of Medtronic, the Associated Press reported.The recalled drug pump was called "SynchroMed II", including models of 8637-20 and 8637-40, distributed between 2004 and July 2011.Drug infusion pump was used to deliver the drugs for patients to treat chronic pain, spasms as well as other conditions.The pumps' malfunction could put patients in the risk of either recurrent or withdrawal symptoms, which could be life-threatening, FDA warned.There were 55 reported cases and one death related to the drug withdrawal, among a total 139,653 SynchroMed II pump implants worldwide, FDA notified.The problem was due to a film within the pump's battery that could stop the therapy, FDA said.Medtronic, the U.S. medical technology company based in Minneapolis, is not recommending patients to remove the pumps, but instead, encourage patients to contact their doctor if they hear the device alarm.

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

来源：资阳报